

International Clinical Trials Day 2016

Clinical Trials Key Facts

There are over **9000** industry-sponsored clinical trials across the world and around **4000** of these in Europe.



Number of Clinical Trials

Clinical Trials are an essential part of the process for over **7000** medicines in currently in development, across a broad range of therapy areas.




Despite flourishing pipelines the number of clinical trials conducted in the EU remains flat, on the contrary, a small decrease over the past years have been identified. The Regulation aims at changing this trend by providing more streamlined submission and assessment process and making Europe a lucrative place to conduct trials.



Clinical trial data will be enhanced by the availability of real world data from patient registries, hospitals and general practitioners.



Over the last 60 years, life expectancy across the EU has increased by nearly a decade. Since the 1980s, death rates from HIV have fallen by around **80%** and since the 1990s, death rates from cancer have fallen by **20%**.



Companies are committed to increasing transparency of clinical trials data. In addition to signing up for the EFPIA-PhRMA principles for responsible clinical trial data sharing, they are also aligning their policies to the new EU Clinical Trials Regulation 536/2014 and the European Medicines Agency's transparency policies: Access to Documents (Policy 0043) and Publication and access to clinical-trial data (Policy 0070)



Due to internationalisation of clinical trials, more EU countries are involved in clinical trial activities, however this has not stopped the overall decline in Europe.



The internationalisation of clinical trials has triggered an increase in the total number of trial applications.



The growing number of investigator sites in Europe suggests that pharmaceutical companies are not planning to scale down clinical trials activities in the region.



Clinical trials account for **58.6%** of the development costs for a new medicine. The biopharmaceutical industry invests more of its revenue in generating new knowledge through research and development than other sectors.

R&D spending as a percentage of net sales, 2014



- 14.4%: Pharmaceuticals and biotechnology
- 10.1%: Software and computer services
- 8%: Technology hardware and equipment
- 4.5%: Aerospace & defence
- 4.4%: Automobiles & parts
- 2.6%: Chemicals